Immune Checkpoint Inhibitors (ICIs) & Primary mediastinal B-cell lymphoma (PMBCL)

The development of Immune Checkpoint Inhibitors (ICIs) like pembrolizumab offers a promising therapeutic avenue for patients with Primary mediastinal B-cell lymphoma (PMBCL), particularly those with relapsed or refractory disease.

References:
Camus et al. 2021 Expert Review of Anticancer Therapy 21(9): 941-956

see also:
CD274 (Programmed death-ligand 1 (PD-L1)) & Primary mediastinal B-cell lymphoma (PMBCL)
Pembrolizumab & Primary mediastinal B-cell lymphoma (PMBCL)